EDIT Stock Discussion

Editas Medicine, Inc. Description

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Genetics Enzymes Genetic Engineering Genome CRISPR DNA Genome Editing Cas9